CD22 and non-Hodgkin lymphoma: Here, we report the clinical and laboratory findings from 95 pediatric patients with R/R B-ALL or B-NHL who received lymphodepletion chemotherapy followed by coadministration of CD19- and CD22- targeted CAR-T cells (19, 20).